Disrupting Disease Specific Aggregation and Biomolecular Condensation
ADRx has unique and proprietary approach to halting diseases of protein aggregation. By utilizing structural insights of aggregated proteins in the form of amyloid and biomolecular condensates the ADRx team has developed ADvantage, a novel drug discovery technology platform to these types of drug targets.
The ADvantage Platform enables discovery and targeting of novel compounds in diseases where no adequate treatment options exist on targets that have been considered undruggable.
ADRx is a privately held preclinical stage biotechnology company located in Thousand Oaks, California.